. Author manuscript; available in PMC: 2014 Jul 7.

Published in final edited form as: Nat Struct Mol Biol. 2013 Dec 8;21(1):36–42. doi: 10.1038/nsmb.2717

Table 2.

Enhancement of GK activity by phospho-mimic BAD BH3 in select MODY2 mutations

Treatment	S_0.5 (mM)	V_max (% WT V_max)	n _H
GK (Wild-type) + Vehicle	5.60 ± 0.06	100	1.73 ± 0.03	n = 8
GK (M298K) + Vehicle	11.3 ± 0.90^***	57.1 ± 4.02^***	1.24 ± 0.05^***	n = 4
GK (M298K) + BAD SAHB_A (S118D)	8.08 ± 0.57^†††	95.7 ± 9.47^†††	1.43 ± 0.04^†	n = 4
GK (E300K) + Vehicle	8.39 ± 0.12^***	84.3 ± 1.89^*	1.83 ± 0.03	n = 4
GK (E300K) + BAD SAHB_A (S118D)	8.02 ± 0.38	103 ± 8.35^†	2.11 ± 0.08^††	n = 4

Summary of mutant GK activity in the absence or presence of BAD SAHB_A (S118D). Kinetic parameters were derived using the Hill equation. Data represent means ± s.e.m.

P < 0.05,

^***

P < 0.001 compared with vehicle treated recombinant human wild-type (WT) GK;

^†

P < 0.05,

^††

P < 0.01,

^†††

P < 0.001 compared with vehicle treated mutant GK; one-way ANOVA.